CStone Pharmaceuticals-B (02616) Announces IND Approval in China for Phase II Clinical Trial of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Combination Therapy, Further Exploring Trispecific Antibody Potential

Stock News

Nov 04, 2025

CStone Pharmaceuticals-B (02616) announced today that the Investigational New Drug (IND) application for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) combination therapy in advanced solid tumors has been approved by China's National Medical Products Administration (NMPA).

Dr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, stated: "The preliminary data from the Phase I study of CS2009 has given us strong confidence, supporting the accelerated advancement of its Phase II research. Accordingly, the Phase II clinical trial adopts a multi-cohort parallel expansion design, encompassing 15 monotherapy/combination therapy cohorts across nine solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Currently, the Phase II trial is actively enrolling patients in Australia. The IND approval in China will further expedite clinical development, allowing deeper exploration and validation of CS2009's broad therapeutic potential."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1109531633"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109531633\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109531633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109531633","market":"us","top_or_hot":-1,"title":"CStone Pharmaceuticals-B (02616) Announces IND Approval in China for Phase II Clinical Trial of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Combination Therapy, Further Exploring Trispecific Antibody Potential","media":"Stock News","content":"<p>CStone Pharmaceuticals-B (02616) announced today that the Investigational New Drug (IND) application for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) combination therapy in advanced solid tumors has been approved by China's National Medical Products Administration (NMPA).</p>\n<p>Dr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, stated: \"The preliminary data from the Phase I study of CS2009 has given us strong confidence, supporting the accelerated advancement of its Phase II research. Accordingly, the Phase II clinical trial adopts a multi-cohort parallel expansion design, encompassing 15 monotherapy/combination therapy cohorts across nine solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Currently, the Phase II trial is actively enrolling patients in Australia. The IND approval in China will further expedite clinical development, allowing deeper exploration and validation of CS2009's broad therapeutic potential.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals-B (02616) Announces IND Approval in China for Phase II Clinical Trial of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Combination Therapy, Further Exploring Trispecific Antibody Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals-B (02616) Announces IND Approval in China for Phase II Clinical Trial of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Combination Therapy, Further Exploring Trispecific Antibody Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-04 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals-B (02616) announced today that the Investigational New Drug (IND) application for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) combination therapy in advanced solid tumors has been approved by China's National Medical Products Administration (NMPA).</p>\n<p>Dr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, stated: \"The preliminary data from the Phase I study of CS2009 has given us strong confidence, supporting the accelerated advancement of its Phase II research. Accordingly, the Phase II clinical trial adopts a multi-cohort parallel expansion design, encompassing 15 monotherapy/combination therapy cohorts across nine solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Currently, the Phase II trial is actively enrolling patients in Australia. The IND approval in China will further expedite clinical development, allowing deeper exploration and validation of CS2009's broad therapeutic potential.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1109531633","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109531633","pubTimestamp":1762214907,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharmaceuticals-B (02616) announced today that the Investigational New Drug (IND) application for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) combination...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","02616":"基石药业-B","BK4023":"应用软件","BK1574":"生物医药B类股"},"translate_title":"基石药业-B(02616)宣布CS2009（PD-1/VEGF/CTLA-4三特异性抗体）联合疗法II期临床试验在中国获IND批准，进一步发掘三特异性抗体潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"02616":1},"content_text":"CStone Pharmaceuticals-B (02616) announced today that the Investigational New Drug (IND) application for the Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) combination therapy in advanced solid tumors has been approved by China's National Medical Products Administration (NMPA).\nDr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, stated: \"The preliminary data from the Phase I study of CS2009 has given us strong confidence, supporting the accelerated advancement of its Phase II research. Accordingly, the Phase II clinical trial adopts a multi-cohort parallel expansion design, encompassing 15 monotherapy/combination therapy cohorts across nine solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Currently, the Phase II trial is actively enrolling patients in Australia. The IND approval in China will further expedite clinical development, allowing deeper exploration and validation of CS2009's broad therapeutic potential.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}